Detalhe da pesquisa
1.
Outcomes in biomarker-selected subgroups from the KESTREL study of durvalumab and tremelimumab in recurrent or metastatic head and neck squamous cell carcinoma.
Cancer Immunol Immunother
; 73(4): 70, 2024 Mar 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38430375
2.
The oDGal Mouse: A Novel, Physiologically Relevant Rodent Model of Sporadic Alzheimer's Disease.
Int J Mol Sci
; 24(8)2023 Apr 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37108119
3.
Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Clin Cancer Res
; 29(11): 2066-2074, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36806911
4.
Selective FFA2 Agonism Appears to Act via Intestinal PYY to Reduce Transit and Food Intake but Does Not Improve Glucose Tolerance in Mouse Models.
Diabetes
; 64(11): 3763-71, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26239054